Wire · opportunities
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Teva has received FDA approval for Weltruza, a once-monthly injectable treatment for adults with schizophrenia, marking their second US-approved product developed with French biotech Medincell. The drug utilizes Medincell's extended-release injectable technology aimed at improving treatment adherence in chronic psychiatric conditions.
This Wire brief sits within Fusion42's coverage of Medtech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You have a new pathway to reach US schizophrenia patients with a long-acting once-monthly injection, cutting through adherence barriers. This FDA nod clears a faster go-to-market window for extended-release antipsychotic treatments in your pipeline.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics